Tamsulosin — $0 with Membership

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Benign Prostatic Hyperplasia

• Alfuzosin
• Doxazosin
• Dutasteride
• Finasteride
• Sildenafil
• Tadalafil

Other medications in Urology

• Terazosin
• Tolterodine
• Vardenafil
• Vibegron
• Avanafil
• Bethanechol
• Ciprofloxacin (UTI)
• Desmopressin Nasal

About Tamsulosin

Tamsulosin is a commonly prescribed medication used to relieve the urinary symptoms associated with an enlarged prostate, also known as Benign Prostatic Hyperplasia (BPH). If you're managing BPH, you know how crucial consistent access to your medication is. The good news? TheDrugClub members can often get tamsulosin for a $0 co-pay with free home delivery, making managing your health easier and more affordable.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Tamsulosin is approved for (FDA label)

Tamsulosin hydrochloride capsules are indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH) [see Clinical Studies (14) ] . Tamsulosin hydrochloride capsules are not indicated for the treatment of hypertension. • Tamsulosin hydrochloride capsules are an alpha 1 adrenoceptor antagonist indicated for treatment of the signs and symptoms of benign prostatic hyperplasia (1) • Tamsulosin hydrochloride capsules are not indicated for the treatment of hypertension (1)

Source: Read the full FDA label on DailyMed. Label effective date: September 1, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Tamsulosin (FDA label)

Capsule: 0.4 mg are olive green opaque/orange opaque size ‘0’ hard gelatin capsules imprinted with ‘D’ on cap and ‘53’ on body with black edible ink filled with white to off-white beadlets. • Capsules: 0.4 mg (3)

Source: FDA prescribing information (DailyMed). Set ID: f8302a6e-b8da-4931-a279-b49e37943816. SPL document ID: 2beef1d9-3ed7-436a-885f-7f8a4dd2ad48. Label effective date: September 1, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Tamsulosin (FDA label)

• The most common adverse events (≥2% of patients and at a higher incidence than placebo) with the 0.4 mg dose or 0.8 mg dose were headache, dizziness, rhinitis, infection, abnormal ejaculation, asthenia, back pain, diarrhea, pharyngitis, chest pain, cough increased, somnolence, nausea, sinusitis, insomnia, libido decreased, tooth disorder, and blurred vision (6.1) To report SUSPECTED ADVERSE REACTIONS, contact Aurobindo Pharma USA, Inc. at 1-866-850-2876 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical studies are conducted under widely varying conditions, adverse reactions rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: f8302a6e-b8da-4931-a279-b49e37943816. SPL document ID: 2beef1d9-3ed7-436a-885f-7f8a4dd2ad48. Label effective date: September 1, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Tamsulosin (FDA label)

Tamsulosin hydrochloride capsules are contraindicated in patients known to be hypersensitive to tamsulosin hydrochloride or any component of tamsulosin hydrochloride capsules. Reactions have included skin rash, urticaria, pruritus, angioedema, and respiratory symptoms [see Adverse Reactions (6.2) ]. • Contraindicated in patients known to be hypersensitive to tamsulosin hydrochloride or any component of tamsulosin hydrochloride capsules (4 , 6.2)

Source: FDA prescribing information (DailyMed). Set ID: f8302a6e-b8da-4931-a279-b49e37943816. SPL document ID: 2beef1d9-3ed7-436a-885f-7f8a4dd2ad48. Label effective date: September 1, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Tamsulosin (FDA label)

• Advise patients about the possibility of symptoms related to postural hypotension and to avoid situations where injury could result should syncope occur (5.1) • Should not be used in combination with strong inhibitors of CYP3A4. Use with caution in combination with moderate inhibitors of CYP3A4, with strong or moderate inhibitors of CYP2D6, in patients known to be CYP2D6 poor metabolizers, or in combination with other cytochrome P450 inhibitors. (5.2 , 7.1 , 12.3) • Should not be used in combination with other alpha adrenergic blocking agents (5.2 , 7.2 , 12.3) • Exercise caution with concomitant administration of warfarin (5.2 , 7.4 , 12.3) • Advise patients about the possibility and seriousness of priapism (5.3) • Intraoperative Floppy Iris Syndrome has been observed during cataract and glaucoma surgery in some patients.

Source: FDA prescribing information (DailyMed). Set ID: f8302a6e-b8da-4931-a279-b49e37943816. SPL document ID: 2beef1d9-3ed7-436a-885f-7f8a4dd2ad48. Label effective date: September 1, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Tamsulosin (FDA label)

• Tamsulosin hydrochloride capsules 0.4 mg should not be used with strong inhibitors of CYP3A4 (e.g., ketoconazole).

Source: FDA prescribing information (DailyMed). Set ID: f8302a6e-b8da-4931-a279-b49e37943816. SPL document ID: 2beef1d9-3ed7-436a-885f-7f8a4dd2ad48. Label effective date: September 1, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.